Bridged bicyclic amino acid-derived [1,4]benzodiazepine vasopressin receptor antagonists

A compound of Formula (I):

• 15
• wherein
• A is a bridged bicycloalkyl ring system of 4 to 7 carbon atoms formed with a nitrogen atom of attachment and E;
• E is selected from the group consisting of a). a —C— atom of attachment bonded to the nitrogen atom of attachment and two carbon atoms of the bridged bicycloalkyl ring system and b). a —CH— atom of attachment bonded to the nitrogen atom of attachment and one carbon atom of the bridged bicycloalkyl ring system;
• R1 is one to four substituents independently selected from the group consisting of hydrogen, C1-8alkyl (optionally substituted on a terminal carbon atom with a substituent selected from the group consisting of aryl, heteroaryl, hydroxy and (halo)1-3), C1-8alkoxy (optionally substituted on a terminal carbon atom with a substituent selected from the group consisting of hydroxy and (halo)1-3), C2-8alkenyl, C2-8alkynyl, aryl, heteroaryl, halogen and hydroxy;
• R2 is selected from the group consisting of —NR4COAr, —NR4CO-heteroaryl, —NR4Ar, —CH═CH—Ar, —CF═CH—Ar, —CH═CF—Ar, —CCl═CH—Ar, —CH═CCl—Ar, —CH═CH-heteroaryl, —CF═CH-heteroaryl, —CH═CF-heteroaryl, —CCl═CH-heteroaryl, —CH═CCl-heteroaryl, —OCH2—Ar, —OCH2-heteroaryl, —SCH2—Ar and —NR4CH2Ar;
• Ar is selected from the group consisting of aryl and heteroaryl optionally substituted with one to five substituents independently selected from the group consisting of C1-8alkyl (optionally substituted on a terminal carbon atom with a substituent selected from the group consisting of aryl, heteroaryl, amino (optionally substituted with one to two substituents selected from C1-8alkyl), hydroxy and (halo)1-3), C1-8alkoxy (optionally substituted on a terminal carbon atom with a substituent selected from the group consisting of aryl, hydroxy and (halo)1-3), aryl, heteroaryl, carboxyl, amino (optionally substituted with one to two substituents selected from C1-8 alkyl), C1-8 alkylsulfonyl, C1-8 alkylsulfinyl, thio (substituted with a substituent selected from the group consisting of C1-8alkyl and (halo)1-3(C1-8)alkyl), cyano, halogen, hydroxy and nitro;
• wherein aryl, heteroaryl and the aryl and heteroaryl portions of any of the foregoing substituents are optionally substituted with one to four substituents independently selected from the group consisting of C1-8alkyl (optionally substituted on a terminal carbon atom with a substituent selected from the group consisting of amino (optionally substituted with one to two substituents selected from C1-8alkyl), hydroxy and (halo)1-3), C1-8alkoxy (optionally substituted on a terminal carbon atom with a substituent selected from the group consisting of hydroxy and (halo)1-3), carboxyl, amino (optionally substituted with one to two substituents selected from C1-8 alkyl), C1-8 alkylsulfonyl, C1-8 alkylsulfinyl, C1-8 alkylthio, cyano, halogen, hydroxy and nitro;
• R3 is one to three substituents independently selected from the group consisting of hydrogen, C1-8alkyl (optionally substituted on a terminal carbon atom with a substituent selected from the group consisting of amino (optionally substituted with one to two substituents selected from C1-8alkyl), hydroxy and (halo)1-3), C1-8alkoxy (optionally substituted on a terminal carbon atom with a substituent selected from the group consisting of hydroxy and (halo)1-3), amino (optionally substituted with one to two substituents selected from C1-8 alkyl), halogen and hydroxy;
• R4 is selected from the group consisting of hydrogen and C1-8 alkyl;
• Y is selected from the group consisting of CH and N;
• and,
• Z is selected from the group consisting of CH2, CH, —C(O)— and —SO2—;
• and pharmaceutically acceptable salts, racemic mixtures, diastereomers and enantiomers thereof.